Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy

Tim A. Ahles, Andrew Saykin, Charlotte T. Furstenberg, Bernard Cole, Leila A. Mott, Linda Titus-Ernstoff, Karen Skalla, Marie Bakitas, Peter M. Silberfarb

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Purpose: This study compared the quality of life (QOL) of long-term survivors of breast cancer and lymphoma who had been treated with standard-dose systemic chemotherapy or local therapy only. Patients and Methods: Long-term survivors (mean, 10.0 ± 5.3 years after treatment) of breast cancer or lymphoma who had been treated with systemic chemotherapy (breast, n = 141, age = 57.0 ± 10.1 years; lymphoma, n = 66, age = 55.8 ± 13.5 years) or local therapy only (breast, n = 294, age = 65.8 ± 9.1 years; lymphoma, n = 37, age = 50.4 ± 12.8 years) were interviewed by phone using the Quality of Life-Cancer Survivors Tool. Results: Multivariate analysis of covariance, controlling for sex, age, education, stage of disease, and time since last treatment, revealed that survivors who had been treated with systemic chemotherapy scored significantly lower on overall QOL compared with survivors treated with local therapy only (P = .04). Analysis of covariance on the subscale scores revealed that, compared with survivors who received local therapy, survivors treated with chemotherapy scored significantly lower on the Social subscale (P <.0001), but no differences emerged on the Psychological or Spiritual subscales. There was a statistically significant interaction between treatment and diagnosis (P = .01), as measured by the Physical subscale, indicating that lymphoma survivors treated with chemotherapy scored worse than all other groups. Conclusion: Important QOL differences emerged between the chemotherapy and local therapy groups, suggesting that long-term QOL may vary depending on the type of treatment and diagnosis.

Original languageEnglish (US)
Pages (from-to)4399-4405
Number of pages7
JournalJournal of Clinical Oncology
Volume23
Issue number19
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Survivors
Lymphoma
Quality of Life
Breast Neoplasms
Drug Therapy
Therapeutics
Breast
Sex Education
Group Psychotherapy
Multivariate Analysis
Psychology
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. / Ahles, Tim A.; Saykin, Andrew; Furstenberg, Charlotte T.; Cole, Bernard; Mott, Leila A.; Titus-Ernstoff, Linda; Skalla, Karen; Bakitas, Marie; Silberfarb, Peter M.

In: Journal of Clinical Oncology, Vol. 23, No. 19, 2005, p. 4399-4405.

Research output: Contribution to journalArticle

Ahles, TA, Saykin, A, Furstenberg, CT, Cole, B, Mott, LA, Titus-Ernstoff, L, Skalla, K, Bakitas, M & Silberfarb, PM 2005, 'Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy', Journal of Clinical Oncology, vol. 23, no. 19, pp. 4399-4405. https://doi.org/10.1200/JCO.2005.03.343
Ahles, Tim A. ; Saykin, Andrew ; Furstenberg, Charlotte T. ; Cole, Bernard ; Mott, Leila A. ; Titus-Ernstoff, Linda ; Skalla, Karen ; Bakitas, Marie ; Silberfarb, Peter M. / Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 19. pp. 4399-4405.
@article{ed2b68ff1d5e4fa5a0cb68b8d0ffaedc,
title = "Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy",
abstract = "Purpose: This study compared the quality of life (QOL) of long-term survivors of breast cancer and lymphoma who had been treated with standard-dose systemic chemotherapy or local therapy only. Patients and Methods: Long-term survivors (mean, 10.0 ± 5.3 years after treatment) of breast cancer or lymphoma who had been treated with systemic chemotherapy (breast, n = 141, age = 57.0 ± 10.1 years; lymphoma, n = 66, age = 55.8 ± 13.5 years) or local therapy only (breast, n = 294, age = 65.8 ± 9.1 years; lymphoma, n = 37, age = 50.4 ± 12.8 years) were interviewed by phone using the Quality of Life-Cancer Survivors Tool. Results: Multivariate analysis of covariance, controlling for sex, age, education, stage of disease, and time since last treatment, revealed that survivors who had been treated with systemic chemotherapy scored significantly lower on overall QOL compared with survivors treated with local therapy only (P = .04). Analysis of covariance on the subscale scores revealed that, compared with survivors who received local therapy, survivors treated with chemotherapy scored significantly lower on the Social subscale (P <.0001), but no differences emerged on the Psychological or Spiritual subscales. There was a statistically significant interaction between treatment and diagnosis (P = .01), as measured by the Physical subscale, indicating that lymphoma survivors treated with chemotherapy scored worse than all other groups. Conclusion: Important QOL differences emerged between the chemotherapy and local therapy groups, suggesting that long-term QOL may vary depending on the type of treatment and diagnosis.",
author = "Ahles, {Tim A.} and Andrew Saykin and Furstenberg, {Charlotte T.} and Bernard Cole and Mott, {Leila A.} and Linda Titus-Ernstoff and Karen Skalla and Marie Bakitas and Silberfarb, {Peter M.}",
year = "2005",
doi = "10.1200/JCO.2005.03.343",
language = "English (US)",
volume = "23",
pages = "4399--4405",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

TY - JOUR

T1 - Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy

AU - Ahles, Tim A.

AU - Saykin, Andrew

AU - Furstenberg, Charlotte T.

AU - Cole, Bernard

AU - Mott, Leila A.

AU - Titus-Ernstoff, Linda

AU - Skalla, Karen

AU - Bakitas, Marie

AU - Silberfarb, Peter M.

PY - 2005

Y1 - 2005

N2 - Purpose: This study compared the quality of life (QOL) of long-term survivors of breast cancer and lymphoma who had been treated with standard-dose systemic chemotherapy or local therapy only. Patients and Methods: Long-term survivors (mean, 10.0 ± 5.3 years after treatment) of breast cancer or lymphoma who had been treated with systemic chemotherapy (breast, n = 141, age = 57.0 ± 10.1 years; lymphoma, n = 66, age = 55.8 ± 13.5 years) or local therapy only (breast, n = 294, age = 65.8 ± 9.1 years; lymphoma, n = 37, age = 50.4 ± 12.8 years) were interviewed by phone using the Quality of Life-Cancer Survivors Tool. Results: Multivariate analysis of covariance, controlling for sex, age, education, stage of disease, and time since last treatment, revealed that survivors who had been treated with systemic chemotherapy scored significantly lower on overall QOL compared with survivors treated with local therapy only (P = .04). Analysis of covariance on the subscale scores revealed that, compared with survivors who received local therapy, survivors treated with chemotherapy scored significantly lower on the Social subscale (P <.0001), but no differences emerged on the Psychological or Spiritual subscales. There was a statistically significant interaction between treatment and diagnosis (P = .01), as measured by the Physical subscale, indicating that lymphoma survivors treated with chemotherapy scored worse than all other groups. Conclusion: Important QOL differences emerged between the chemotherapy and local therapy groups, suggesting that long-term QOL may vary depending on the type of treatment and diagnosis.

AB - Purpose: This study compared the quality of life (QOL) of long-term survivors of breast cancer and lymphoma who had been treated with standard-dose systemic chemotherapy or local therapy only. Patients and Methods: Long-term survivors (mean, 10.0 ± 5.3 years after treatment) of breast cancer or lymphoma who had been treated with systemic chemotherapy (breast, n = 141, age = 57.0 ± 10.1 years; lymphoma, n = 66, age = 55.8 ± 13.5 years) or local therapy only (breast, n = 294, age = 65.8 ± 9.1 years; lymphoma, n = 37, age = 50.4 ± 12.8 years) were interviewed by phone using the Quality of Life-Cancer Survivors Tool. Results: Multivariate analysis of covariance, controlling for sex, age, education, stage of disease, and time since last treatment, revealed that survivors who had been treated with systemic chemotherapy scored significantly lower on overall QOL compared with survivors treated with local therapy only (P = .04). Analysis of covariance on the subscale scores revealed that, compared with survivors who received local therapy, survivors treated with chemotherapy scored significantly lower on the Social subscale (P <.0001), but no differences emerged on the Psychological or Spiritual subscales. There was a statistically significant interaction between treatment and diagnosis (P = .01), as measured by the Physical subscale, indicating that lymphoma survivors treated with chemotherapy scored worse than all other groups. Conclusion: Important QOL differences emerged between the chemotherapy and local therapy groups, suggesting that long-term QOL may vary depending on the type of treatment and diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=22344458235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22344458235&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.343

DO - 10.1200/JCO.2005.03.343

M3 - Article

VL - 23

SP - 4399

EP - 4405

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 19

ER -